Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology company that focuses on developing neurogenetic medicines. The company aims to alter the progression of neurological diseases, with a pipeline targeting conditions like Alzheimer’s disease and amyotrophic lateral sclerosis. As it prepares to release its quarterly earnings on March 11, 2025, analysts expect an earnings per share (EPS) of -$0.35 and revenue of approximately $16.6 million.
Voyager's financial metrics provide insight into its current market position. The company has a price-to-earnings (P/E) ratio of 9.52, which suggests a relatively low valuation compared to its earnings. This could be attractive to investors looking for value in the biotechnology sector. Additionally, the price-to-sales ratio of 1.42 indicates that investors are paying $1.42 for every dollar of sales, which is reasonable for a company in this industry.
The enterprise value to sales ratio of 1.01 reflects Voyager's valuation in relation to its revenue, suggesting that the market values the company close to its sales figures. However, the negative enterprise value to operating cash flow ratio of -6.21 highlights potential challenges in generating cash flow from operations, which could be a concern for investors.
Despite these challenges, Voyager's financial health appears stable. The company has a low debt-to-equity ratio of 0.14, indicating a conservative use of debt in its capital structure. This is complemented by a strong current ratio of 8.45, showing that Voyager has a robust ability to cover its short-term liabilities with its short-term assets. The earnings yield of 10.50% offers a measure of return on investment for shareholders, which may be appealing to those seeking income from their investments.
